WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
Tweet
Share
E-mailGet Alerts AKBA Hot Sheet
Price: $0.92 -1.08%
Rating Summary:
13 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 70
Rating Summary:
13 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 70
Join SI Premium – FREE
WestPark Capital initiates coverage on Akebia Therapeutics (NASDAQ: AKBA) with a Buy rating and a price target of $4.50.
For an analyst ratings summary and ratings history on Akebia Therapeutics click here. For more ratings news on Akebia Therapeutics click here.
Shares of Akebia Therapeutics closed at $0.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Starts Lumexa Imaging Holdings (LMRI) at Overweight
- CFRA Double Upgrades Everpure (P) to Buy
- Rockwell Automation CRO to retire at end of 2026
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
